Watch for Phase 2 MoMeNtum top-line results in December 2026, which will be a key catalyst for the MMN program. The CIDP CAPTIVATE Part A results by YE'27 and gMG EMERGE results in 2H'28 are longer-term milestones. The $1.2B cash runway into 2030 removes near-term financing risk.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $83.01entry
- T+1 · 11d ago +3.64%α +3.33% · $86.03
- T+5 · 5d ago +11.41%α +8.12% · $92.48
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dianthus Therapeutics reported Q3 2026 net loss of $46.6M ($0.81 per share), wider than the $36.8M loss in Q3 2025, but the EPS of -$0.81 beat the consensus estimate of -$0.95. The company highlighted strong clinical progress across its pipeline, including a 75% response rate in the CIDP Phase 3 CAPTIVATE trial interim analysis and a $1.2B cash runway into 2030.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $46.6M ($0.81 per share) vs $36.8M ($0.97 per share) in Q3 2025
- EPS of -$0.81 beat consensus estimate of -$0.95
- Revenue of $1.21M (license revenue) vs $396K in Q3 2025, well above $389K consensus
- Cash, cash equivalents and investments of ~$1.2B as of Sep 30, 2026, providing runway into 2030
- Phase 3 CAPTIVATE trial in CIDP showed 75% response rate in interim analysis of first 40 participants
- Phase 2 MoMeNtum trial in MMN top-line results expected December 2026
- Phase 3 EMERGE trial in gMG on track with top-line results expected 2H'28
- R&D expenses increased to $45.6M from $32.5M YoY, driven by clinical costs and headcount
Financial Impact
Net loss of $46.6M in Q3 2026, wider than $36.8M in Q3 2025; cash burn rate increased with R&D spend up 40% YoY
Risk Factors
- Clinical-stage biotech with no approved products; all programs are investigational
- Phase 3 CAPTIVATE interim analysis based on only 40 patients; results may not be predictive of full trial
- Increasing R&D and G&A expenses driving wider net losses
- Pipeline relies on successful clinical trial execution across multiple indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395769 |
Track record
23 reports on DNTH
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers